News Medical on MSN1d
Certain genetic alterations may contribute to primary resistance of certain cancers to KRAS G12C inhibitorsThe KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma ...
In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, ...
The BIRAC funding will enable comprehensive toxicology assessments, a necessary step in preparing for IND submission with ...
Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...
For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...
PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer ...
In addition, the Company announced that it will host "The Future of Food” event, an exclusive culinary experience led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback